Phase 2 vaccine candidate, VLA15, is being evaluated for adult and pediatric indications in North America and Europe.    Saint Herblain (France) and New York, NY, April 30, 2020 – Valneva SE (“Valneva”), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced a collaboration to develop and commercialize Valneva’s Lyme disease vaccine candidate … Continue reading Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15